Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C

Trial Profile

Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anamorelin (Primary)
  • Indications Anorexia; Cachexia
  • Focus Registrational; Therapeutic Use
  • Acronyms ROMANA-1
  • Sponsors Helsinn Therapeutics
  • Most Recent Events

    • 07 Jun 2022 Results of this post-hoc analysis from ROMANA 1 and 2 presented at the 58th Annual Meeting of the American Society of Clinical Oncology
    • 21 Sep 2020 Results of a post hoc analysis of data pooled from ROMANA 1and 2studies assessing anorexia symptoms and concerns reported by pts with advanced non-small cell lung cancer and cachexia on the basis of their BMI and weight loss degree, presented at the 45th European Society for Medical Oncology Congress
    • 12 Sep 2017 Results (n=829) of pooled post hoc analysis of NCT01387269 and NCT01387282 assessing the baseline characteristics of patients with mGPS 0-2 presented at the 42nd European Society for Medical Oncology Congress
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top